KKR has acquired Medicover, a Sweden-based international healthcare and diagnostic services provider, in a deal valued at $1.4 billion. The transaction, announced on Tuesday, will see the private equity firm take full ownership of the company, which is currently listed on Nasdaq Stockholm. Medicover’s shareholders will receive the agreed price per share, with the acquisition expected to close following regulatory approvals.
Medicover, founded in 1995 and headquartered in Sweden, operates across 19 countries with a workforce exceeding 48,000 people. Its largest markets include Poland, Germany, Romania, India, and Ukraine. The company is organised into two primary divisions: Healthcare Services, which covers outpatient clinics, hospitals, specialist care, fertility treatment, dental and optician services, as well as wellbeing offerings such as sports packages and diets; and Diagnostic Services, which provides a broad range of clinical laboratory tests spanning routine to advanced pathology areas.
For KKR, the acquisition represents a move to consolidate its presence in the European healthcare sector, where demand for private medical services and diagnostic testing has grown steadily. Medicover’s integrated model, combining care delivery with laboratory operations, offers a diversified revenue base across multiple geographies. The purchase gives KKR control of a platform that can be scaled further, particularly in Central and Eastern Europe and India, where healthcare infrastructure remains underdeveloped relative to demand.
The deal is expected to provide Medicover with greater financial flexibility to expand its network of clinics and laboratories without the short-term reporting pressures of public markets. KKR’s operational expertise in healthcare investments may also support efficiency improvements across Medicover’s diagnostic and outpatient services. No changes to Medicover’s management or day-to-day operations have been announced, and the company will continue to operate under its existing brand.
Post-acquisition, Medicover is set to pursue its long-term growth strategy with private backing, focusing on deepening its footprint in existing markets and potentially entering new ones. The completion of the deal will mark the end of Medicover’s tenure as a publicly traded entity, shifting its focus toward long-horizon investments in capacity and service quality.